Shots:

• The companies initiate P-III SAMETA study to evaluate the efficacy and safety of Hutchmed’s savolitinib (MET tyrosine kinase inhibitor) + AstraZeneca’s Imfinzi (PD-L1 inhibitor) in treatment-naïve patients with MET-driven advanced PRCC. The first patient was dosed on Oct 28, 2021
• The 1EPs of the study is m-PFS & other EPs include m-OS, ORR, DoR, 6 & 12mos. DCR, time to second progression (PFS2), safety, PK, and QoL
• In 2011, the companies collaborated to jointly develop & commercialize savolitinib where Hutchmed will lead marketing authorization, manufacturing & supply of the therapy in China & AstraZeneca is responsible for the commercialization globally

Ref: Globenewswire | Image: AstraZeneca